ITOS iTeos Therapeutics: Forward P/S Multiple
iTeos Therapeutics (ITOS) is a promising player in immuno-oncology, developing breakthrough molecules to combat cancer. This chart of the company's future P/S visualizes market expectations, while 11.00 shows the current value of the metric. Stable demand for healthcare gives the asset defensive qualities, and the synergy between US and Belgian experts ensures the development of bold scientific ideas.
ITOS (iTeos Pharma): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity iTeos Therapeutics|ITOS - Long-Term Liabilities to Capital|Short-Term Debt to Equity iTeos Therapeutics|ITOS - Company Total Debt Obligations|Debt to Book Value iTeos Pharma|ITOS - Company Long-Term Loans and Borrowings|Company Current Liabilities iTeos Therapeutics|Quick Ratio iteostherapeutics.com
- net income and valuation multiples indicators:
ITOS - Final Profit|Projected Future Earnings iTeos Therapeutics|ITOS - Market Cap to Earnings|Future Price to Earnings iTeos|ITOS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple iTeos Pharma|ITOS - Operating profit EBITDA|Earnings per share for the last twelve months iTeos Therapeutics|ITOS - Earnings per one share for the last 12 months|Quarterly EPS earnings growth iteostherapeutics.com|ITOS - Earnings per share growth rate in current year|Expected earnings per share growth for next year iTeos Therapeutics
- issuer revenue and sales details:
Comprehensive company analysis:iTeos Therapeutics, Inc. (ITOS)
The stability of iTeos Therapeutics (ITOS) is underpinned by R&D patent protection and strategic alliances with pharmaceutical behemoths, which establish a robust financial foundation. The forward P/S ratio trend reflects the relationship between market capitalization and expected sales, allowing investors to assess the premium paid for future growth and determine the fair balance between speculative expectations and the business's actual fundamental potential.
Key competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|Abivax Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio ADMA Corp ADMA|PTGX (Protagonist Therapeutics) - Forward Price-to-Revenue Multiple|IMVT: Price to Expected Revenue Ratio|KNSA (Kiniksa) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grifols SA GRFS|Price-to-Projected Revenue Ratio Adaptive Biotechnologies Corp (ADPT)|CLDX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Aurinia Pharmaceuticals AUPH|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|VERA: Forward Price-to-Revenue Multiple|Forward Price to Sales DNTH (Dianthus Therapeutics Inc)|PHVS (Pharvaris Corp) - Forward Price-to-Revenue Multiple|ABCL: Price to Expected Revenue Ratio|TRML (Tourmaline Bio, Inc.) - Forward P/S Multiple|PGEN: Forward Price to Sales|Forward P/S Multiple PHAR|NKTR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Upstream Bio Corp UPB|Forward Price to Sales ZBIO|Immunome, Inc. - Forward P/S Multiple|GOSS - Forward P/S Multiple|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Future Price to Revenue SEPN (Septerna, Inc.)|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Savara Pharma SVRA|Forward Price-to-Revenue Multiple RIGL (Rigel Pharmaceuticals)|Forward P/S Multiple anaptysbio.com (ANAB)|Astria Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ENGN (enGene Holdings Inc)|RAPT Therapeutics, Inc. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Aerovate Therapeutics Inc JBIO|ACRS: Forward P/S Multiple|Forward Price-to-Revenue Multiple kyvernatx.com|Price-to-Projected Revenue Ratio Tiziana Life Sciences Ltd|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VTYX|Market Cap to Expected Sales Ratio Theratechnologies, Inc|Avalo Therapeutics, Inc - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ELDN (eledon.com)|AGEN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Climb Bio Inc.|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|ATYR - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Adagene Inc|Ikena Oncology, Inc. - Future Price to Revenue|Forward P/S Multiple STTK|EQ (equilliumbio.com) - Forward Price to Sales|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Forward P/S Multiple Immunic Therapeutics IMUX|ATRA - Price-to-Projected Revenue Ratio|Forward Price to Sales IFRX (InflaRx N.V.)|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adicet Bio, Inc.|CELU (Celularity Inc) - Forward P/S Multiple|Forward P/S Multiple INmune Bio Corporation|Forward Price-to-Revenue Multiple BRNS (Barinthus Biotherapeutics)|KZR (kezarlifesciences.com) - Forward Price to Sales|Forward P/S Multiple SABS (SAB Biotherapeutics, Inc.)|Market Cap to Expected Sales Ratio Akari Therapeutics PLC (AKTX)|ENLV - Price-to-Projected Revenue Ratio|Q32 Bio Inc. (QTTB) - Forward Price-to-Revenue Multiple|GeoVax Labs, Inc. (GOVX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple edesabiotech.com|Forward Price-to-Revenue Multiple IBIO|Forward P/S Multiple Carisma Tx|Price-to-Projected Revenue Ratio XTL Biopharmaceuticals, Ltd. (XTLB)|boltbio.com - Market Cap to Projected Revenue|Forward P/S Multiple HCWB (HCW Biologics)|Aptevo Therapeutics, Inc. (APVO) - Market Cap to Future Revenue Ratio|AIM ImmunoTech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Aditxt ADTX|GRI (GRI Bio Corp) - Forward Price-to-Revenue Multiple|XRTX: Price to Expected Revenue Ratio|HIND (Vyome Holdings Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio revbiosciences.com REVB|Price-to-Projected Revenue Ratio Indaptus Therapeutics, Inc. (INDP)|SCNI - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio CalciMedica CALI|Market Cap to Expected Sales Ratio Affimed NV (AFMD)|ALLK: Forward Price-to-Revenue Multiple|Forward Price to Sales HOOK (HOOKIPA Pharma Inc.)|IGMS (igmbio.com) - Forward Price-to-Revenue Multiple|OCEA: Price to Expected Revenue Ratio|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|THRD: Forward Price to Sales
